Rinatabart sesutecan (Rina-S®) in advanced ovarian cancer and advanced or recurrent endometrial cancer: Results from dose-optimization cohorts in the phase 1/2 RAINFOL™-01 study

International Journal of Gynecological Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles